Polymer Capital Management HK LTD Purchases New Stake in Regeneron Pharmaceuticals, Inc. $REGN

Polymer Capital Management HK LTD purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 3,704 shares of the biopharmaceutical company’s stock, valued at approximately $2,310,000.

Several other institutional investors have also recently bought and sold shares of REGN. Western Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $26,000. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $26,000. Titan Wealth CI Ltd bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $29,000. Kemnay Advisory Services Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. Finally, Birchwood Financial Partners Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the sale, the director owned 603 shares of the company’s stock, valued at approximately $482,400. The trade was a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $834.04 on Monday. The stock has a 50 day moving average of $697.09 and a 200 day moving average of $716.46. The company has a market capitalization of $85.87 billion, a price-to-earnings ratio of 20.61, a PEG ratio of 1.42 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $847.00. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same quarter in the previous year, the firm earned $12.81 earnings per share. The business’s revenue was up 16.7% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Leerink Partners lifted their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Canaccord Genuity Group reduced their target price on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Finally, Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Sixteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $801.70.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.